Holen Sie sich die Stockscreener-App
4.29
0.94%
0.04
Handel nachbörslich:
4.29
Schlusskurs vom Vortag:
$4.25
Offen:
$4.29
24-Stunden-Volumen:
328.14K
Relative Volume:
0.99
Marktkapitalisierung:
$173.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.75M
KGV:
-0.9914
EPS:
-4.327
Netto-Cashflow:
$-50.79M
1W Leistung:
+2.39%
1M Leistung:
+35.76%
6M Leistung:
+45.92%
1J Leistung:
+77.27%
1-Tages-Spanne:
$4.18
$4.50
1-Wochen-Bereich:
$4.015
$4.545
52-Wochen-Spanne:
$1.91
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Firmenname
Onkure Therapeutics Inc
Sektor
Branche
Telefon
(720) 307-2892
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.29 | 169.66M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-05 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-10 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Eingeleitet | William Blair | Outperform |
| 2023-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-03 | Eingeleitet | BofA Securities | Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
OKUR Q1 2026 Earnings: EPS Miss by 46.55% Signals Aggressive Pipeline InvestmentEarnings Revision Upgrade - newsline.com
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
OnKure Therapeutics (OKUR) director receives 7,650 stock options grant - Stock Titan
OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike - Stock Titan
Director at OnKure (NASDAQ: OKUR) receives 7,650 stock options - Stock Titan
OnKure (OKUR) awards director 7,650 stock options at $4.30 - Stock Titan
OnKure (OKUR) director receives 7,650 options at $4.30 strike - Stock Titan
OnKure (OKUR) director awarded 7,650 stock options at $4.30 strike - Stock Titan
Onkure Therapeutics patents new PI3Kα mutant inhibitors - BioWorld News
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageSlow Growth Warning - newsline.com
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan - The Globe and Mail
OnKure (NASDAQ: OKUR) holders back equity plan changes and board slate - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady Near Support: Can $4.43 Resistance Be Breached?Breakout Confirmation - newsline.com
OKUR Q1 2026 Earnings: EPS Miss of 46.6% Highlights Early-Stage R&D CostsGuidance Upgrade Report - thelegaladvocate.com
OnKure Therapeutics (OKUR) Advances 2.55% as Stock Holds Above Key SupportBollinger Expansion - The Legal Advocate
OKUR Q1 2026 Earnings: Wider EPS Loss Underscores Heavy R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Surprise Stocks - newsline.com
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEarnings Stability Report - The Legal Advocate
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineMargin Guidance - The Legal Advocate
Survey finds most Boulder residents satisfied with quality of life - BizWest
OnKure Therapeutics (OKUR) Surges 14% Amid Renewed Investor InterestMerger Arbitrage - Newser
OnKure Therapeutics (OKUR) Q1 2026 Earnings Miss: EPS $-1.11 vs $-0.76 ExpectedReal Trader Insights - Newser
OnKure Therapeutics (OKUR) Jumps +7.88% on Strong Momentum 2026-05-20Technical Analysis Picks - The Legal Advocate
ADAR1 entities and Daniel Schneeberger report 6.0% of OnKure (NASDAQ: OKUR) - Stock Titan
TradingKey - TradingKey
The long term thesis for OnKure Therapeutics (OKUR) in plain sight (Breakdown Watch) 2026-05-11Social Momentum Signals - newser.com
OnKure Therapeutics (OKUR) Receives a Rating Update from a Top Analyst - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
OnKure Therapeutics war chest nears $200M following spring stock sale - BizWest
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target - TipRanks
Oppenheimer Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Onkure Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] OnKure Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
OnKure (Nasdaq: OKUR) lifts cash to $192.1 million after raise - Stock Titan
OnKure bets on 2 PI3K drugs for breast cancer and vascular anomalies - Stock Titan
OnKure Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
OnKure Therapeutics Reports First Quarter 2026 Financial Results - marketscreener.com
[EFFECT] OnKure Therapeutics, Inc. SEC Filing - Stock Titan
Aclarion reports cash runway to ops into late 2027 - BizWest
What date does OnKure Therapeutics, Inc.'s (OKUR) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60 - MSN
OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
OnKure Therapeutics prices $150M oversubscribed private placement - MSN
What top holdings OnKure Therapeutics (OKUR)? (Smart Money Active) 2026-04-27Earnings Beat Stocks - Newser
OKUR (OnKure Therapeutics) reports narrower Q4 2025 loss than estimates, shares drop 2.04 percent in trading.Revenue Growth Rate - Newser
Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Drops By 57.6% - MarketBeat
Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Onkure Therapeutics Inc-Aktie (OKUR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Mar 23 '26 |
Sale |
4.16 |
301 |
1,251 |
16,000 |
| Saccomano Nicholas A | President and CEO |
Dec 22 '25 |
Sale |
2.97 |
87 |
258 |
7,419 |
| Leverone Jason A. | Chief Financial Officer |
Dec 22 '25 |
Sale |
2.97 |
302 |
896 |
16,301 |
| Saccomano Nicholas A | President and CEO |
Sep 22 '25 |
Sale |
2.62 |
88 |
231 |
3,506 |
| Leverone Jason A. | Chief Financial Officer |
Sep 22 '25 |
Sale |
2.62 |
303 |
795 |
12,603 |
| Saccomano Nicholas A | President and CEO |
Jun 23 '25 |
Sale |
2.38 |
88 |
210 |
3,594 |
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):